WMGI - Wright Medical To Acquire Cartiva For Great Toe Damage Treatment

Quick Take

Wright Medical Group (WMGI) has announced it has agreed to acquire Cartiva for $435 million.

Cartiva develops cartilage injury and osteoarthritis treatment products.

WMGI is paying a reasonable price for Cartiva’s fast-growing and easy-to-sell implant product.

Target Company

Alpharetta, Georgia,-based Cartiva was founded in 2011 to improve the quality of life for patients with osteoarthritis or cartilage damage through the development of novel medical device treatments.

Cartiva’s lead product, a Synthetic Cartilage Implant ((SCI)) for treating arthritis at the base of the great toe, received U.S. Premarket Approval in July 2016.